A61K 45 - Medicinal preparations containing active ingredients not provided for in groups

Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
11/2006
11/22/2006	EP1724351A2 Human Kallikrein-like genes
11/22/2006	EP1724349A1 TIE Ligand Homologues
11/22/2006	EP1724339A1 Gene regulation therapy involving ferritin
11/22/2006	EP1724270A2 Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents
11/22/2006	EP1724267A1 Pyrimidine derivative
11/22/2006	EP1723971A1 Methods and compositions for the treatment of viral diseases
11/22/2006	EP1723970A1 Medicinal composition containing cxcr3 inhibitor
11/22/2006	EP1723969A1 Granulocyte-macrophage colony-stimulating factor (GM-CSF) as remedy for nerve damages
11/22/2006	EP1723968A1 Erythrocyte function modifying substance
11/22/2006	EP1723967A2 Soluble lymphotoxin-beta receptors, anti-lymphotoxin receptor antibodies and anti-lymphotoxin ligand antibodies as therapeutic agents for the treatment of immunological diseases
11/22/2006	EP1723957A2 Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
11/22/2006	EP1723953A1 Nutritional supplements
11/22/2006	EP1723950A2 Method of treating dopaminergic gaba-nergic disorders
11/22/2006	EP1723948A1 Controlled release compositions of biguanide with less side effects and treatment regimen thereof
11/22/2006	EP1723253A2 Inhibitors of siderophore biosynthesis in fungi
11/22/2006	EP1723160A1 Toll-like receptor 2 (tlr-2) haplotypes predict outcome of patients
11/22/2006	EP1723147A1 Process for inhibiting cell proliferation
11/22/2006	EP1722802A1 A medical solution, a method for producing said medical solution and use thereof
11/22/2006	EP1722801A1 Use of enhanced water to improve blood sugar management
11/22/2006	EP1722780A1 A method of preventing or treating glaucoma
11/22/2006	EP1722766A2 Management of ophthalmologic disorders, including macular degeneration
11/22/2006	EP1722762A2 Nanocell drug delivery system
11/22/2006	EP1722645A1 Solubilized coq-10 and carnitine
11/22/2006	EP1722630A2 Compositions and methods of treatment for inflammatory diseases
11/22/2006	EP1539184B1 Estrogen replacement regimen
11/22/2006	EP1534265B1 Combination of an aromatase inhibitor with a bisphosphonate
11/22/2006	EP1499392B1 Method and agents for the prevention, inhibition, and therapy of cancers
11/22/2006	EP1438049B1 Substituted 4-phenyl-4-(1h-imidazol-2-yl)-piperidine derivatives for reducing ischaemic damage
11/22/2006	EP1432402B1 Compositions for delivery of drug combinations
11/22/2006	EP1429756B1 Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
11/22/2006	EP1420778B1 Use of mek inhibitors for treating virus induced hemorrhagic shock or fever
11/22/2006	EP1407261A4 In vivo bioreactors
11/22/2006	EP1401413B1 Use of tyrosine kinase inhibitions for treating allergic diseases
11/22/2006	EP1361899B1 Silicon implants comprising a radionucleotide for use in brachytherapy
11/22/2006	EP1317450B1 Pyrazole compounds useful as protein kinase inhibitors
11/22/2006	EP1299081B1 Use of oligosaccharides to stimulate beta-endorphin production
11/22/2006	EP1220682B1 Stabilized liquid polypeptide-containing pharmaceutical compositions
11/22/2006	EP1194777B1 Methods and compositions relating to pancreatic islet and beta-cell dysfunction
11/22/2006	EP1173465B1 Novel human voltage-gated potassium channel
11/22/2006	EP1163522B1 Method for detecting msrv-1 induced superantigen activity in a biological sample
11/22/2006	EP1146899B1 Methods of using neurotrophin 3 (nt-3) for the treatment of gastrointestinal hypomotility disorders
11/22/2006	EP1120114B1 Compositions and methods for treating conditions responsive to estrogen
11/22/2006	EP1096924B1 Inhibitors of proteasomal activity for stimulating hair growth
11/22/2006	EP0939821B1 G-beta-gamma regulated phosphatidylinositol-3' kinase
11/22/2006	EP0935415B1 In vitro methods for delivering nucleic acids into a cell
11/22/2006	EP0825996B1 Fibroblast growth factor homologous factor-1 (fhf-1) and methods of use
11/22/2006	CN1867358A Combination of a serotonin reuptake inhibitor and a glycine transporter type 1 inhibitor for the treatment of depression
11/22/2006	CN1867340A Topical use of halosalicylic acid derivatives
11/22/2006	CN1867337A Methods for intradermal delivery of therapeutics agents
11/22/2006	CN1867258A Stable liquid probiotic composition, preparation and applications thereof
11/22/2006	CN1867252A Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
11/22/2006	CN1865248A Imidazole-4-carboxamide derivatives, preparation and use thereof for treatment of obesity
11/22/2006	CN1864748A Preparation of dopamine agonist and application thereof
11/22/2006	CN1285591C Dimeric compounds and their use as anti-viral agents
11/22/2006	CN1285572C Cannabinod receptor ligands
11/22/2006	CN1285382C Nasal administered drug delivery system containing mycose and hyaluronic acid and method for preparing same
11/21/2006	US7138546 Compounds and compositions for delivering active agents
11/21/2006	US7138542 Administering a therapeutically effective amount of an alpha2delta ligand other than gabapentin or tiagabine, or pharmaceutically acceptable salt thereof
11/21/2006	US7138501 Antibodies that immunospecifically bind BLyS
11/21/2006	US7138499 antibody that binds to a peptide of given amino acid sequence related to the sulfotransferase drug-metabolizing enzyme subfamily
11/21/2006	US7138492 Promoting survival of substantia nigra neuronal cells by contacting with a trophic amount of a ptc therapeutic; mimics hedgehog-mediated patched signal transduction; treating or preventing Parkinson's Disease
11/21/2006	US7138430 Nitrosated and nitrosylated nebivolol and its metabolites, compositions and methods of use
11/21/2006	US7138426 Estrogen receptor modulators
11/21/2006	US7138394 Vehicle for topical delivery of anti-inflammatory compounds
11/21/2006	US7138379 Use of the interferon receptor 2c polypeptide chain to enhance the anti-growth effects of type I interferons
11/21/2006	US7138376 Composition for treating a host infected with a hepatitis C viral comprising administering an effective hepatitis C treatment amount of a described 4'-disubstituted nucleoside or a pharmaceutically acceptable salt or prodrug thereof
11/21/2006	US7138375 treating Type II diabetes, eating disorders, and insulin-resistance syndrome with exendin peptide analogs
11/21/2006	US7138370 Anticancer agents; skin disorders; antiinflamamtory agents; antiarthritic agents
11/21/2006	US7138243 NTB-A, a surface molecule involved in natural killer cells activity
11/21/2006	US7138147 Arsenic sulfide compounds and derivatives thereof for the treatment of malignancies
11/21/2006	US7138146 Acrochordon alleviation
11/21/2006	US7138134 Preparation and administration of jojoba product for reducing weight, fat and blood lipid levels
11/21/2006	US7138122 Therapeutic systems
11/21/2006	US7138119 Compositions and methods for inhibition of HIV-1 infection
11/21/2006	US7138115 Administering monoclonal or polyclonal antibody to treat multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes melitis and autoimmune inflammatory eye disease
11/21/2006	US7138114 Pharmaceutical compositions of fibrinolytic agent
11/21/2006	CA2478621C Botulinum toxin pharmaceutical compositions
11/21/2006	CA2433386C Compositions and methods involving an essential staphylococcus aureus gene and its encoded protein staau_r9
11/21/2006	CA2253736C Antimicrobial treatment for herpes simplex virus and other infectious diseases
11/21/2006	CA2247611C Method and composition for hair removal
11/21/2006	CA2164061C Cosmetic compositions containing lactate dehydrogenase inhibitors
11/16/2006	WO2006122060A1 Compositions and uses of secreted polypeptide, zsig98
11/16/2006	WO2006121666A2 Delivery of tigecycline in the presence of warfarin
11/16/2006	WO2006121219A1 Agent for controlling epithelial-mesenchymal transition
11/16/2006	WO2006120568A2 Pharmaceutical composition containing an anti parasitic agent and an active ingredient selected from carveol, thymol, eugenol, borneol, carvacrol, alpha-ionone, or beta-ionone
11/16/2006	WO2006120567A2 Pharmaceutical composition comprising an anti-bacterial agent and an active ingredient selected from carveol, thymol, eugenol, borneol and carvacrol
11/16/2006	WO2006120565A2 Pharmaceutical combination comprising an antifungal agent and an active substance selected from carveol, eugenol, thymol, borneol, carvacrol and alpha- and beta-ionones
11/16/2006	WO2006120564A1 Pharmaceutical composition comprising an antiviral agent, an antitumoral agent or an antiparasitic agent, and an active agent selected among carveol, thymol, eugenol, borneol and carvacrol
11/16/2006	WO2006120557A1 Anticancer combination therapy using sunitinib malate
11/16/2006	WO2006120496A1 Pharmaceutical combination comprising an antifungal agent and an active substance selected from carveol, eugenol, thymol, borneol and carvacrol
11/16/2006	WO2006120495A1 Pharmaceutical composition comprising an antiviral agent, an antitumour agent or an antiparasitic agent and an active substance selected from carveol, thymol, eugenol, borneol and carvacrol
11/16/2006	WO2006120494A1 Pharmaceutical combination comprising an antibacterial agent and an active substance selected from carveol, thymol, eugenol, borneol and carvacrol
11/16/2006	WO2006120360A2 Active composition for treatment or prevention of problems related to a disturbance of the biological clock
11/16/2006	WO2006119958A2 Use of flibanserin in the treatment of chronic pain
11/16/2006	WO2006119692A1 A medicament for the treatment of hypertension
11/16/2006	WO2006050489A3 Methods of entrapping, inactivating, and removing viral infections by the administration of respiratory tract compositions
11/16/2006	WO2005089803A3 Pharmaceutical compositions for the treatment of skin diseases comprising a combination of epinastine and one or more additional minerals or one or more crude drugs
11/16/2006	WO2005080030A3 Colloid, method of obtaining colloid or its derivatives and applications thereof
11/16/2006	WO2003073916A8 Immune regulation
11/16/2006	WO2002094236A9 Delivery of antipsychotics through an inhalation route

1 ... 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 ... 1151